-
Stereotaxis completes first procedures with Genesis system in Netherlands
-
Stereotaxis (STXS) Tops Q2 EPS by 2c
-
Stereotaxis receives FDA clearance for robotic mapping catheter
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
Stereotaxis (STXS) Reports In-Line Q1 EPS
-
TD Cowen Reiterates Buy Rating on Stereotaxis (STXS)
-
Stereotaxis (STXS) Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program
-
Stereotaxis (STXS) Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery
-
Stereotaxis (STXS) Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance
-
Stereotaxis (STXS) Announces First GenesisX Robotic System Order
-
Stereotaxis (STXS): Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China’s NMPA
-
Stereotaxis (STXS) Genesis Robotic System Achieves Regulatory Approval in China
-
Piper Sandler Reiterates Overweight Rating on Stereotaxis (STXS)
-
Stereotaxis (STXS) Misses Q3 EPS by 3c
-
TD Cowen Reiterates Buy Rating on Stereotaxis (STXS)
-
Roth/MKM Reiterates Buy Rating on Stereotaxis (STXS)
-
Stereotaxis (STXS) Misses Q2 EPS by 2c
-
Stereotaxis (STXS) Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
-
Stereotaxis (STXS) Strengthens Board of Directors with Appointment of Nachum Shamir

